012790 — Sinil Pharmaceutical Co Balance Sheet
0.000.00%
- KR₩71bn
- KR₩33bn
- KR₩89bn
Annual balance sheet for Sinil Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 14,593 | 20,870 | 23,354 | 23,419 | 33,713 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 21,192 | 20,721 | 23,713 | 22,845 | 20,839 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 52,772 | 58,427 | 67,280 | 68,787 | 77,449 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 32,150 | 30,999 | 35,744 | 41,916 | 44,789 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 124,810 | 128,974 | 142,832 | 152,460 | 165,861 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 10,387 | 12,023 | 15,959 | 14,145 | 16,453 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 17,326 | 15,777 | 19,554 | 17,565 | 19,356 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Total Equity | 107,484 | 113,196 | 123,277 | 134,895 | 146,506 |
| Total Liabilities & Shareholders' Equity | 124,810 | 128,974 | 142,832 | 152,460 | 165,861 |
| Total Common Shares Outstanding |